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We present our experience with a four-year (2004–2008)
follow-up of a child with multiple autoimmune syn-
dromes.
SB, now 13 years old, was symptomatic since 2.5 years
with relapsing hepatitis, eventually diagnosed at age 6
years, as chronic lobular hepatitis (ANA positive,
AntiLKM/Antimicrosomal/AntiSmoothMuscle Antibod-
ies negative).
At 4 years, she was detected to have Type 1 Diabetes Mel-
litus (Islet Cell Antibodies positive) and she presented to
us at 9 years, with Dermatomyositis (Gottrons papules,
CPK 12,310 units, CMAS 2/52).
She was started on steroids and azathioprine. Her insulin
requirements increased from 20 units/day to 120–140
units/day and she needed a dose of 0.5 mg/kg/day of
prednisolone to keep a near normal CMAS and muscle
enzymes within normal limits.
In October 2007, azathioprine was substituted by subcu-
taneous methotrexate (10 mg/m2). This led to reduction
of daily prednisolone to 0.1 mg/kg/day, improved glyc-
emic control, halving the insulin requirements, improved
growth, with no worsening of liver function. She was
started on Growth Hormone in 2008 for short stature and
this has not altered her glycemic control till the time of
reporting. She has hyperlipidemia controlled with diet
and statins but has not developed candidiasis or other
endocrinopathies during follow up.
In conclusion, despite her previous auto-immune liver
disease, methotrexate has proven thus far to be a safe and
effective steroid sparer in the management of her dermat-
omyositis
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